FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2970293522> ?p ?o ?g. }

• W2970293522 endingPage "1247" @default.
• W2970293522 startingPage "1247" @default.
• W2970293522 abstract "Choroideremia (CHM) is a rare, degenerative, genetic retinal disorder resulting from mutation of the CHM gene, leading to an absence of functional ras-associated binding escort protein 1 (REP1). There is currently no approved treatment for CHM.To assess the safety and efficacy of retinal gene therapy with an adeno-associated virus vector (AAV2) designed to deliver a functional version of the CHM gene (AAV2-REP1) for treatment of patients with choroideremia.Tübingen Choroideremia Gene Therapy (THOR) was a single-center, phase 2, open-label randomized clinical trial. Data were collected from January 11, 2016, to February 26, 2018. Twenty-four-month data are reported for 6 men with a molecularly confirmed diagnosis of CHM. Intention-to-treat analysis was used.Patients received AAV2-REP1 by a single, 0.1-mL subretinal injection of 1011 genome particles during vitrectomy into 1 eye randomly assigned to receive treatment.Primary end point was change in best-corrected visual acuity (BCVA) on the Early Treatment Diabetic Retinopathy Study chart from baseline to month 24 in the treated eye vs the control eye. Secondary end points included microperimetry variables, change in fundus autofluorescence, and spectral-domain optical coherence tomographic evaluations from baseline to month 24 in the treated eye vs the control eye.On enrollment, the mean (SD) age of the 6 men included in the study was 54.9 (4.1) years. The mean (SD) BCVA score was 60.3 (13.4) (approximately 20/63 Snellen equivalent) in the study eyes and 69.3 (20.6) (approximately 20/40 Snellen equivalent) in the control eyes. At 24 months, the BCVA change was 3.7 (7.5) in the treated eyes and 0.0 (5.1) in the control eyes (difference, 3.7; 95% CI, -7.2 to 14.5; P = .43). Mean change in retinal sensitivity was 10.3 (5.5) dB in the treated eyes and 9.7 (4.9) dB in the control eyes (difference, 0.6; 95% CI, -10.2 to 11.4; P = .74). A total of 28 adverse events were reported; all were consistent with the surgical procedure (eg, conjunctival hyperemia, foreign body sensation), and none were regarded as severe.Among 6 participants, gene therapy with AAV2-REP1 was associated with maintenance or improvement of visual acuity, although no significant difference was found from control eyes. All safety issues were associated with the surgical procedure and none were judged severe. Continued investigations could more precisely define the efficacy and safety of gene therapy with AAV2-REP1 in CHM.ClinicalTrials.gov identifier: NCT02671539." @default.
• W2970293522 created "2019-09-05" @default.
• W2970293522 creator A5002031142 @default.
• W2970293522 creator A5004643937 @default.
• W2970293522 creator A5008582328 @default.
• W2970293522 creator A5012100527 @default.
• W2970293522 creator A5021919197 @default.
• W2970293522 creator A5031581635 @default.
• W2970293522 creator A5034341833 @default.
• W2970293522 creator A5037669782 @default.
• W2970293522 creator A5037907056 @default.
• W2970293522 creator A5043310900 @default.
• W2970293522 creator A5043630025 @default.
• W2970293522 creator A5046326117 @default.
• W2970293522 creator A5052981823 @default.
• W2970293522 creator A5055206709 @default.
• W2970293522 creator A5058499472 @default.
• W2970293522 creator A5074250540 @default.
• W2970293522 date "2019-11-01" @default.
• W2970293522 modified "2023-10-17" @default.
• W2970293522 title "Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia" @default.
• W2970293522 cites W2000072353 @default.
• W2970293522 cites W2017986205 @default.
• W2970293522 cites W2018410059 @default.
• W2970293522 cites W2024160187 @default.
• W2970293522 cites W2028156947 @default.
• W2970293522 cites W2044913417 @default.
• W2970293522 cites W2074854567 @default.
• W2970293522 cites W2126115955 @default.
• W2970293522 cites W2342947338 @default.
• W2970293522 cites W2562473836 @default.
• W2970293522 cites W2612647476 @default.
• W2970293522 cites W2620920205 @default.
• W2970293522 cites W2652146858 @default.
• W2970293522 cites W2748086397 @default.
• W2970293522 cites W2768317657 @default.
• W2970293522 cites W2794187230 @default.
• W2970293522 cites W2810681605 @default.
• W2970293522 cites W2890721979 @default.
• W2970293522 cites W2893026352 @default.
• W2970293522 cites W2897506831 @default.
• W2970293522 cites W4247169198 @default.
• W2970293522 cites W4285698150 @default.
• W2970293522 cites W4320300927 @default.
• W2970293522 doi "https://doi.org/10.1001/jamaophthalmol.2019.3278" @default.
• W2970293522 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6865291" @default.
• W2970293522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31465092" @default.
• W2970293522 hasPublicationYear "2019" @default.
• W2970293522 type Work @default.
• W2970293522 sameAs 2970293522 @default.
• W2970293522 citedByCount "60" @default.
• W2970293522 countsByYear W29702935222020 @default.
• W2970293522 countsByYear W29702935222021 @default.
• W2970293522 countsByYear W29702935222022 @default.
• W2970293522 countsByYear W29702935222023 @default.
• W2970293522 crossrefType "journal-article" @default.
• W2970293522 hasAuthorship W2970293522A5002031142 @default.
• W2970293522 hasAuthorship W2970293522A5004643937 @default.
• W2970293522 hasAuthorship W2970293522A5008582328 @default.
• W2970293522 hasAuthorship W2970293522A5012100527 @default.
• W2970293522 hasAuthorship W2970293522A5021919197 @default.
• W2970293522 hasAuthorship W2970293522A5031581635 @default.
• W2970293522 hasAuthorship W2970293522A5034341833 @default.
• W2970293522 hasAuthorship W2970293522A5037669782 @default.
• W2970293522 hasAuthorship W2970293522A5037907056 @default.
• W2970293522 hasAuthorship W2970293522A5043310900 @default.
• W2970293522 hasAuthorship W2970293522A5043630025 @default.
• W2970293522 hasAuthorship W2970293522A5046326117 @default.
• W2970293522 hasAuthorship W2970293522A5052981823 @default.
• W2970293522 hasAuthorship W2970293522A5055206709 @default.
• W2970293522 hasAuthorship W2970293522A5058499472 @default.
• W2970293522 hasAuthorship W2970293522A5074250540 @default.
• W2970293522 hasBestOaLocation W29702935221 @default.
• W2970293522 hasConcept C104317684 @default.
• W2970293522 hasConcept C111599444 @default.
• W2970293522 hasConcept C118487528 @default.
• W2970293522 hasConcept C2778257484 @default.
• W2970293522 hasConcept C2779100554 @default.
• W2970293522 hasConcept C2779418775 @default.
• W2970293522 hasConcept C2780827179 @default.
• W2970293522 hasConcept C54355233 @default.
• W2970293522 hasConcept C71924100 @default.
• W2970293522 hasConcept C86803240 @default.
• W2970293522 hasConceptScore W2970293522C104317684 @default.
• W2970293522 hasConceptScore W2970293522C111599444 @default.
• W2970293522 hasConceptScore W2970293522C118487528 @default.
• W2970293522 hasConceptScore W2970293522C2778257484 @default.
• W2970293522 hasConceptScore W2970293522C2779100554 @default.
• W2970293522 hasConceptScore W2970293522C2779418775 @default.
• W2970293522 hasConceptScore W2970293522C2780827179 @default.
• W2970293522 hasConceptScore W2970293522C54355233 @default.
• W2970293522 hasConceptScore W2970293522C71924100 @default.
• W2970293522 hasConceptScore W2970293522C86803240 @default.
• W2970293522 hasIssue "11" @default.
• W2970293522 hasLocation W29702935221 @default.
• W2970293522 hasLocation W29702935222 @default.
• W2970293522 hasLocation W29702935223 @default.
• W2970293522 hasOpenAccess W2970293522 @default.

• next